These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 37500165

  • 1. Inhibitory Effect of Pyra-Metho-Carnil on Cancer Spheroid Growth Through Decrease in Glycolysis-associated Molecules.
    Yoshida K, Nishi K, Ishikura S, Matsumoto T, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2023 Aug; 43(8):3717-3726. PubMed ID: 37500165
    [Abstract] [Full Text] [Related]

  • 2. Cancer Spheroid Proliferation Is Suppressed by a Novel Low-toxicity Compound, Pyra-Metho-Carnil, in a Context-independent Manner.
    Yoshida K, Nishi K, Ishikura S, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2022 Aug; 42(8):3993-4001. PubMed ID: 35896235
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory Effect of Pyra-Metho-Carnil on the Differentiation and Maturation of Macrophages in Normal and Cancer Microenvironments.
    Kitaguchi T, Matsumoto T, Yoshida K, Hamaguchi Y, Maruta G, Maeoka H, Ishikura S, Nakano M, Ishida Y, Hirai F, Aoki M, Kodama S, Shirasawa S, Tsunoda T.
    Anticancer Res; 2024 Aug; 44(8):3557-3565. PubMed ID: 39060056
    [Abstract] [Full Text] [Related]

  • 4. Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.
    Nishi K, Luo H, Ishikura S, Doi K, Iwaihara Y, Wills L, Baillie GS, Sakata T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2017 Jul; 37(7):3833-3839. PubMed ID: 28668883
    [Abstract] [Full Text] [Related]

  • 5. MK615 Suppresses Hypoxia Tolerance by Up-regulation of E-cadherin in Colorectal Cancer Cells With Mutant KRAS.
    Nishi K, Tsunoda T, Uchida Y, Sueta T, Sawatsubashi M, Yamano T, Hashiguchi Y, Swain A, Shirasawa S, Sakata T.
    Anticancer Res; 2020 Aug; 40(8):4687-4694. PubMed ID: 32727793
    [Abstract] [Full Text] [Related]

  • 6. Growth Suppression of Human Colorectal Cancer Cells with Mutated KRAS by 3-Deaza-cytarabine in 3D Floating Culture.
    Luo H, Nishi K, Ishikura S, Swain A, Morishige N, Yazaki R, Ohshima T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2018 Jul; 38(7):4247-4256. PubMed ID: 29970558
    [Abstract] [Full Text] [Related]

  • 7. Growth Suppression of Cancer Spheroids With Mutated KRAS by Low-toxicity Compounds from Natural Products.
    Hashimoto S, Nagai M, Nishi K, Ishikura S, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2021 Aug; 41(8):4061-4070. PubMed ID: 34281875
    [Abstract] [Full Text] [Related]

  • 8. A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation.
    Okamoto H, Matsukawa T, Doi S, Tsunoda T, Sawata Y, Naemura M, Ohnuki K, Shirasawa S, Kotake Y.
    Mol Cell Biochem; 2018 May; 442(1-2):39-45. PubMed ID: 28936721
    [Abstract] [Full Text] [Related]

  • 9. Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules.
    Tsunoda T, Ishikura S, Doi K, Iwaihara Y, Hidesima H, Luo H, Hirose Y, Shirasawa S.
    Anticancer Res; 2015 Aug; 35(8):4453-9. PubMed ID: 26168486
    [Abstract] [Full Text] [Related]

  • 10. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation.
    Charitou T, Srihari S, Lynn MA, Jarboui MA, Fasterius E, Moldovan M, Shirasawa S, Tsunoda T, Ueffing M, Xie J, Xin J, Wang X, Proud CG, Boldt K, Al-Khalili Szigyarto C, Kolch W, Lynn DJ.
    Br J Cancer; 2019 Jul; 121(1):37-50. PubMed ID: 31133691
    [Abstract] [Full Text] [Related]

  • 11. Targeting metabolic reprogramming in KRAS-driven cancers.
    Kawada K, Toda K, Sakai Y.
    Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
    [Abstract] [Full Text] [Related]

  • 12. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC, Xu J, Bian X, Wu JL, Kang W, Qian Y, Li W, Chen H, Gou H, Liu D, Yat Luk ST, Zhou Q, Ji F, Chan LS, Shirasawa S, Sung JJ, Yu J.
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [Abstract] [Full Text] [Related]

  • 13. Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion.
    Nishi K, Ishikura S, Umebayashi M, Morisaki T, Inozume T, Kinugasa T, Aoki M, Nimura S, Swain A, Yoshida Y, Hasegawa S, Nabeshima K, Sakata T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2020 Aug; 40(8):4663-4674. PubMed ID: 32727790
    [Abstract] [Full Text] [Related]

  • 14. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T.
    Theranostics; 2020 Aug; 10(11):5107-5119. PubMed ID: 32308771
    [Abstract] [Full Text] [Related]

  • 15. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
    Matsubara H, Miyoshi H, Kakizaki F, Morimoto T, Kawada K, Yamamoto T, Obama K, Sakai Y, Taketo MM.
    Mol Cancer Ther; 2023 Apr 03; 22(4):529-538. PubMed ID: 36780229
    [Abstract] [Full Text] [Related]

  • 16. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY.
    Int J Mol Sci; 2021 Jul 14; 22(14):. PubMed ID: 34299137
    [Abstract] [Full Text] [Related]

  • 17. Mediatory role of BLT2 in the proliferation of KRAS mutant colorectal cancer cells.
    Park J, Jang JH, Kim JH.
    Biochim Biophys Acta Mol Cell Res; 2019 Mar 14; 1866(3):329-336. PubMed ID: 30553812
    [Abstract] [Full Text] [Related]

  • 18. Combination Therapy with KRAS and P38α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line.
    Kamran S, Seyedrezazadeh E, Shanehbandi D, Asadi M, Zafari V, Shekari N, Namvar L, Zarredar H.
    J Gastrointest Cancer; 2022 Sep 14; 53(3):597-604. PubMed ID: 34292499
    [Abstract] [Full Text] [Related]

  • 19. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.
    Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, Roper J, Chio II, Giannopoulou EG, Rago C, Muley A, Asara JM, Paik J, Elemento O, Chen Z, Pappin DJ, Dow LE, Papadopoulos N, Gross SS, Cantley LC.
    Science; 2015 Dec 11; 350(6266):1391-6. PubMed ID: 26541605
    [Abstract] [Full Text] [Related]

  • 20. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA, Spolverato G, Kim Y, Karagkounis G, Choti MA, Pawlik TM.
    Ann Surg Oncol; 2015 Dec 11; 22(13):4158-65. PubMed ID: 26077912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.